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ABSTRACT Influenza A virus (IAV) causes annual epidemics of respiratory disease in
humans, often complicated by secondary coinfection with bacterial pathogens such
as Staphylococcus aureus. Here, we report that the S. aureus secreted protein lipase 1
enhances IAV replication in vitro in primary cells, including human lung fibroblasts.
The proviral activity of lipase 1 is dependent on its enzymatic function, acts late in
the viral life cycle, and results in increased infectivity through positive modulation of
virus budding. Furthermore, the proviral effect of lipase 1 on IAV is exhibited during
in vivo infection of embryonated hen’s eggs and, importantly, increases the yield of
a vaccine strain of IAV by approximately 5-fold. Thus, we have identified the first S.
aureus protein to enhance IAV replication, suggesting a potential role in coinfection.
Importantly, this activity may be harnessed to address global shortages of influenza
vaccines.
IMPORTANCE Influenza A virus (IAV) causes annual epidemics and sporadic pan-
demics of respiratory disease. Secondary bacterial coinfection by organisms such as
Staphylococcus aureus is the most common complication of primary IAV infection
and is associated with high levels of morbidity and mortality. Here, we report the
first identified S. aureus factor (lipase 1) that enhances IAV replication during infec-
tion via positive modulation of virus budding. The effect is observed in vivo in em-
bryonated hen’s eggs and greatly enhances the yield of a vaccine strain, a finding
that could be applied to address global shortages of influenza vaccines.
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Influenza A virus (IAV) is a member of the Orthomyxoviridae family, with a segmented,negative-sense RNA genome. Aquatic birds are viewed as the reservoir host, but it
infects a wide variety of vertebrate hosts, including birds, bats, and terrestrial and
aquatic mammals (1). The virus is antigenically diverse and across all hosts has at least
18 subtypes of the major surface glycoprotein, hemagglutinin (HA), and 11 of the
lower-abundance neuraminidases (NA) (2). A common feature of all HA subtypes is that
the molecule is synthesized as a precursor (HA0) that, after assembly into a trimer, must
be proteolytically cleaved into HA1 and HA2 subunits to produce infectious virus
particles (3). This cleavage step is achieved in cell culture by the addition of trypsin to
the media, while secreted trypsin-like proteases of respiratory or mucosal epithelia
perform this role in human seasonal IAV infections or low-pathogenicity avian influenza
virus infections (4). Virus replication is entirely dependent on this step, making it an
attractive target for therapeutic intervention (5).
In humans, IAV causes annual epidemics of respiratory illness with an estimated
annual mortality rate of 290,000 to 600,000 worldwide (6). Sporadic pandemics, asso-
ciated with antigenically novel IAV strains, can lead to increased morbidity and mor-
tality compared to seasonal epidemics (7). Secondary bacterial coinfection is the most
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common complication of primary IAV, and a high incidence is reported during both
epidemics and pandemics. The two bacterial species most commonly isolated from IAV
coinfection patients are the Gram-positive species Streptococcus pneumoniae and
Staphylococcus aureus (8). During the most devastating human IAV pandemic, the 1918
H1N1 subtype “Spanish flu,” bacterial coinfection was identified in 70% to 90% of
autopsies (7). In the most recent pandemic of 2009, 25% to 40% of mortalities were
attributed to bacterial coinfection, despite the widespread use of antibiotics (9, 10).
S. aureus is found as a commensal organism in around 25% to 40% of the healthy
human population but is responsible for an array of diseases, ranging from uncompli-
cated skin and soft tissue infections to life-threatening conditions, such as endocarditis
and necrotizing pneumonia (11). Of note, the emergence of highly virulent clones of
community-associated methicillin-resistant S. aureus (CA-MRSA) in recent years has
resulted in S. aureus becoming the leading cause of nosocomial pneumonia in the
United States (12). The role of immune dysregulation during coinfection has been
extensively studied, and it is believed to be one of the main underlying causes for the
increased susceptibility to bacterial coinfection following primary influenza (8). The
contribution of individual S. aureus factors is less known. In vivo, the SaeR/S system has
been shown to contribute to coinfection in a murine model (13). In vitro, phenol-soluble
modulins have been demonstrated to be more cytotoxic in lung epithelial cells (ECs)
previously infected with IAV (14), and incubation with IAV resulted in virus bound to
bacterial cells and increased adherence of S. aureus to epithelial cells (15). Additionally,
Tashiro and colleagues (16, 17) reported that S. aureus strain Wood 46 secretes a
protease which can substitute for (or augment) the host proteases required to activate
IAV HA, thereby enhancing the production of infectious viral particles. However, the
identity of this protein remained unknown (16, 17), hindering further investigation into
possible intervention mechanisms.
In the current study, we investigated the ability of secreted proteins of S. aureus to
enhance IAV replication in vitro. Unexpectedly, we discovered that a single polypeptide,
lipase 1, potentiates IAV replication in vitro and in vivo, independently of all known S.
aureus proteases. Lipase 1 acts during the late stages of IAV replication, separately from
HA cleavage, leading to an increase in the number of infectious particles produced.
These findings expand on our understanding of the molecular events that occur during
IAV-S. aureus coinfection and identify a novel role for one of the most abundant S.
aureus-secreted proteins (18).
RESULTS
S. aureus proviral activity is mediated by the lipolytic activity of lipase 1. A
previous study by Tashiro et al. reported that activity of an S. aureus-secreted protease
enhanced IAV replication via HA cleavage (16, 17). However, S. aureus produces a wide
array of proteins involved in pathogenesis, including 10 secreted proteases (19). To
investigate further the role of S. aureus proteases during influenza coinfection, we
repeated the protocol employed by Tashiro et al. and fractionated culture supernatants
of S. aureus strains Wood 46 (Fig. 1A), USA300 LAC and a deletion mutant of USA300
LAC deficient in the production of all known secreted proteases (20) (see Fig. S1A and
B in the supplemental material) by size exclusion chromatography (SEC). Aliquots of the
resulting SEC fractions were added to primary chicken embryo fibroblast (CEF) cells
infected with the H1N1 IAV strain A/Puerto Rico/8/34 (PR8) to test for their ability to
support virus replication in the absence of exogenous trypsin. As expected, the addition
of trypsin increased virus titer several-hundred-fold compared to samples with no
exogenous protease (Fig. 1B). Fractions 2 to 4 from both Wood 46 and USA300 LAC
culture supernatants also showed significantly increased virus replication (Fig. 1B),
consistent with the original report of Tashiro et al. (17). However, unexpectedly,
supernatant fractions from the protease-deficient USA300 LAC strain retained proviral
activity equivalent to that of the wild-type (WT) fractions (Fig. 1B), indicating that the
pro-IAV activity was independent of the presence of known secreted proteases.
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To identify the bacterial factor responsible for the observed proviral effect, the S.
aureus SEC fractions were further separated by ion-exchange chromatography (IEC;
Fig. S1C), after which 3 samples were found to have consistently retained proviral
activity (Fig. 1C). These were analyzed by tryptic digestion followed by liquid
FIG 1 S. aureus lipase 1 is proviral for IAV in vitro. (A) Supernatants from S. aureus cultures were separated by SEC and 10-l
volumes of the first 10 fractions separated by SDS-PAGE and stained for total protein. Representative images of USA300
LAC fractions are shown. U, unfractionated. (B) CEF cells were infected with PR8 at an MOI of 0.01 and, immediately
postabsorption, treated with trypsin (T; 2.5 g/ml) or aliquots of unfractionated or fractionated supernatants from the
indicated S. aureus strains. Virus titers were determined by plaque assay at 48 hpi and normalized to the level of an
untreated control. (C) SEC fractions 2 to 4 from WT USA300 LAC were pooled and separated by IEC before testing for
pro-IAV activity was performed as described above. Data shown are means  standard errors of the means of results from
3 independent infections. (D) Cells of transposon (tn) insertion mutants of indicated genes or a plasmid-complemented
(Lip1::tn pLip1) strain were grown and supernatants separated by SEC before testing for proviral activity was performed.
Fractions were tested separately, but data shown represent the average values of results from fractions 1 to 5. (E) Increasing
concentrations of purified rlipase 1 or rlipase 2 were added to CEF cells infected with PR8 at MOI 0.01. Infections were
harvested after 48 h and infectious titers determined. (F) Aliquots of purified recombinant wild-type or catalytic site mutant
(S408) lipase 1 were analyzed by SDS-PAGE and staining with Coomassie blue or Western blotting with anti-histidine IgG.
(G) A final concentration of 300 nM lipase 1 or lipase 1 S408A was added to CEF cells infected with PR8 at MOI 0.01.
Infections were harvested after 48 h and infectious titers determined. Numerical data shown are means  standard errors
of the means of results from 3 independent protein preparations (B, D, E, and G). Single asterisks (*), double asterisks (**),
and triple asterisks (***) indicate P values of 0.05, 0.01, and0.001, respectively, based on Student’s t test, compared
to virus-only controls (B, C, and E), Tn-Lip1 (D and E), and rlipase 1 (F and G) results.
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chromatography-tandem mass spectrometry (LC-MS/MS), and two proteins, lipase 1
(gehA) and lipase 2 (gehB), were found to be common to the active fractions (see
Table S1 in the supplemental material). The proviral activity of these and of two other
high-scoring mass spectrometry candidates, N-acetylmuramoyl-L-alanine amidase
domain-containing protein (amidase) and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were tested by utilizing the Nebraska transposon (Tn) mutant library, con-
structed in the USA300 LAC background (21). Culture supernatants from the relevant Tn
insertion mutants were fractionated by SEC and tested for their ability to promote IAV
replication as described above. Disruption of the lipase 2, amidase, or GAPDH genes
had no impact on the proviral activity of USA300 culture supernatants (Fig. 1D). In
contrast, disruption of the lipase 1 gene reduced the stimulatory activity to background
levels. Furthermore, the proviral phenotype could be restored by complementation of
the lipase 1 Tn mutant with a plasmid encoding lipase 1 (pLip1; Fig. 1D). Taken
together, these data demonstrate that the observed proviral activity of S. aureus
USA300 LAC is dependent on the presence of lipase 1.
To further characterize the effect of S. aureus lipase 1 on IAV replication, we
produced polyhistidine-tagged recombinant forms of both lipase 1 (rlipase 1) and the
paralog lipase 2 (rlipase 2) in Escherichia coli and purified them by immobilized metal
affinity chromatography (IMAC) (Fig. S2A and B). Both protein preparations exhibited
concentration-dependent lipolytic activity in vitro, with lipase 2 showing higher activity
than lipase 1 (Fig. S2C and D), consistent with previous reports (5, 18, 22). When CEF
cells infected with IAV PR8 were incubated with the recombinant S. aureus lipase 1
(rlipase 1), there was a concentration-dependent increase in IAV titer, whereas recom-
binant lipase 2 (rlipase 2) had no proviral effect (Fig. 1E). The lipolytic activity of lipase
1 has been mapped to serine 408 and histidine 643 (5), so to test if the proviral
phenotype of the protein was due to lipase activity, a site-directed mutant form of
rlipase 1 (rlipase 1 S408A), with the serine replaced by alanine, was similarly produced
in E. coli and purified (Fig. 1F). Importantly, mutation of the active site of rlipase 1
dramatically reduced both the lipolytic activity (Fig. S2E) and the proviral activity
(Fig. 1G) of the protein, suggesting that the lipase enzymatic activity was responsible
for the proviral effect.
S. aureus lipase 1 acts during a single IAV replication cycle. To examine further
the rlipase 1 effect on IAV, growth of the virus in the presence of rlipase 1 was
investigated in detail. IAV requires specific proteolytic cleavage of HA to produce
infectious virus capable of initiating a new cycle of infection. In vitro, this is normally
mediated by exogenously added trypsin. As expected, infection of CEFs at a low
multiplicity of infection (MOI) with trypsin supported at least two successful rounds of
infection (Fig. 2A, gray squares). Infection at low MOI with rlipase 1, in the absence of
exogenous protease, resulted in enhanced IAV replication during the first replication
cycle but thereafter had little effect (Fig. 2A, blue triangles). However, when the partially
trypsin-independent virus A/WSN/33 (WSN) (23, 24) was utilized, rlipase 1 increased
virus yield across the whole time course, with true multicycle replication kinetics
(Fig. 2B). Growth under high-MOI conditions similarly demonstrated that the presence
of rlipase 1 increased IAV titer during a single round of replication for both strains of
IAV (Fig. 2C and D). Thus, rlipase 1 enhanced replication of a trypsin-dependent IAV in
a single replication cycle but did not support multiple rounds of infection, suggesting
that it was not acting as if it were mediating proteolytic cleavage of HA.
Lipase 1 is broadly proviral for IAV. Lipase 1 has been reported to be one of the
most abundantly secreted factors during the stationary phase of growth in the USA300
LAC strain (18). However, the distribution and level of expression of lipase 1 among S.
aureus strains are poorly understood. Examination of 8,334 publicly available S. aureus
genomes identified the lipase 1 gene (gehA) in 8,274 (99.3%), indicating broad conser-
vation across the species (data not shown). Furthermore, Western blotting of culture
supernatants from 19 clinical isolates using an antibody specific for lipase 1 detected
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expression in 16 (84%) isolates under nutrient-rich in vitro conditions (Fig. S3), indicat-
ing that lipase 1 is broadly expressed by S. aureus strains.
To investigate if rlipase 1 had proviral activity for other strains of IAV and if this could
extend to human cells, infections were performed using the H3N8 A/equine/Miami/63
(Miami) strain and primary normal human lung fibroblast (NHLF) cells. Importantly,
rlipase 1 enhanced replication of PR8 and Miami in both CEF and NHLF cells, respec-
tively, but rlipase 2 did not (Fig. 3A and B). To determine the breadth of the proviral
activity of rlipase 1, we tested a range of IAV strains in CEF and NHLF cells, under both
single-cycle and multicycle growth conditions. Proviral activity was observed for all
viruses tested, including avian strains, and for both cell types (Table 1). Taken together,
these data demonstrate that rlipase 1 has broad proviral activity for IAV in human cells.
We also performed infections in relevant primary and continuous cell lines, including
Madin Darby canine kidney (MDCK) cells (used for IAV quantification by plaque assay),
A549 human lung epithelial cells, DF1 cells (a spontaneous immortalized derivative of
primary CEF cells), and primary human bronchial-tracheal epithelial cells (HBTECs). Of
note, we did not observe a rlipase 1-mediated increase in viral titer in any of these cell
lines (Fig. 3C and D) or in HBTECs (Fig. S4). Taken together, these data suggest that the
proviral phenotype of S. aureus rlipase 1 may be specific for cells that are primary and
that are of fibroblast origin.
Lipase 1 exerts proviral activity during the late stages of IAV replication. We
considered that the increase in the number of infectious particles seen during a single
infectious cycle might have been due to (i) increased levels of attachment and entry, (ii)
more-efficient production of virus components, or (iii) improved assembly and release
from the cell. To investigate this, rlipase 1 was added at different stages of a single-cycle
FIG 2 Lipase 1 increases viral replication during a single infectious cycle. CEF cells were infected with
PR8 (A) or WSN (B) at an MOI of 0.01 or with PR8 (C) or WSN (D) at an MOI of 3 in multicycle experiments
(A and B) or single-cycle experiments (C and D). PBS or a final concentration of 300 nM rlipase 1 or
2.5 g/ml trypsin was added immediately postinoculum removal. Infectious titers were determined at
the indicated times. Data shown are means standard errors of the means of results from 4 independent
recombinant protein preparations. A single asterisk (*) indicates a P value of 0.05 for results of
comparisons between the virus group without lipase 1 and the virus group with lipase 1, and a
crosshatch symbol (#) indicates a P value of 0.05 for results of comparisons between the virus group
without trypsin and the virus group with trypsin, based on Student’s t test.
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infection (Fig. 4A). The presence of rlipase 1 before infection or during virus absorption
did not lead to an increase in titer. However, addition of rlipase 1 after the absorption
period at any time up to the first 6 h postinfection (hpi) resulted in significant increases
in titer, whereas addition at 7 h onward had no significant influence. These data
suggested that rlipase 1 was not affecting the attachment and/or internalization of the
virus but was acting later in the replication cycle. It is also possible that rlipase 1 affects
virus replication in both early and late events, a scenario that this experimental setup
could not exclude. To determine if rlipase 1 induced increased production of viral
components, we analyzed the accumulation of viral proteins at different time points.
No differences were observed between virus-infected cells and infected cells treated
with rlipase 1 (Fig. 4B). Furthermore, analysis of intracellular viral RNA also showed no
FIG 3 Lipase 1 proviral activity is restricted to primary cells. The indicated cell lines were infected with
PR8 (A and C) or Miami (B and D) IAV at an MOI of 0.01 and a final concentration of 300 nM rlipase 1 or
rlipase 2 or of 2.5 g/ml trypsin was added. Infectious titers were determined after 48 h. All data shown
are means  standard errors of the means of results from 3 independent protein preparations. A single
asterisk (*) indicates a P value of 0.05, based on a Student’s t test, compared to the virus-only control.
TABLE 1 Lipase 1 is proviral for a range of mammalian and avian viruses in primary human and avian fibroblastsa
Virus Host Subtype
Avg fold titer increase (SD)
CEF cells NHLF cells
MOI 0.01 MOI 3 MOI 0.01 MOI 3
A/Puerto Rico/8/34 Human H1N1 14.2 (3.2) 11.4 (4.1) 5.72 (2.7) 4.69 (2.9)
A/Equine/Miami/63 Horse H3N8 12.6 (3.3) 9.85 (5.1) 7.50 (4.7) 2.32 (0.9)
A/Udorn/307/72 Human H3N2 14.7 (5.3) 10.4 (0.78) 5.73 (2.2) 3.60 (1.9)
A/Duck/England/62 Duck H4N6 207.2 (88.8) 13.8 (6.1) 6.94 (3.2) 11.25 (5.4)
A/Turkey/Canada/63 Turkey H3N2 57.7 (32.6) 64.6 (38.5) Not tested Not tested
A/Mallard/Netherlands/10/99 Duck H1N1 54.4 (29.1) 15.5 (6.1) Not tested Not tested
aCEF or NHLF cells were infected with the indicated viruses at a MOI of 0.01 or 3, and 300 nM rlipase 1 was added immediately after inoculum removal. Samples were
harvested at 24 h (MOI of 3) or 48 h (MOI of 0.01) and infectious viral titers determined by plaque assay. Data are expressed as the average ( standard deviation)
fold increase in titer compared to parallel samples incubated without trypsin and represent results from 3 independent experiments.
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significant differences between treated and untreated cells in the levels of accumula-
tion of viral segment 2 or viral segment 7 RNAs produced (Fig. 4C). Therefore, rlipase
1 did not seem to be affecting viral macromolecular synthesis, thus suggesting an effect
on assembly and/or release. To investigate the final steps of viral replication, we
quantified the amounts of viral genome (a measure of overall virus particle formation)
and infectious particles released into the culture supernatant. The addition of either
active rlipase 1 or the catalytically inactive S408A mutant had no significant effect on
the amounts of viral genomic RNA released at 8 hpi, but as before, the presence of
active rlipase 1 but not inactive rlipase 1 significantly increased the titer of infectious
virus (Fig. 4D). Consequently, this caused a significant decrease in the genome copy
number/PFU ratio of the virus population (Fig. 4E). Similar effects were seen when
earlier (6 hpi) or later (10 hpi) time points were analyzed (Fig. S5A and B), indicating that
rlipase 1 increased the infectivity of released virus. The original analysis of the molecular
basis of S. aureus enhancement of IAV disease postulated that a bacterial protease was
responsible for cleaving viral HA (16, 17). To determine if lipase 1 was able to cleave HA,
FIG 4 Lipase 1 increases the ratio of infectious particles produced during an infection. (A) CEF cells were treated with a final concentration of
300 nM rlipase 1 for the periods indicated by the blue lines before or after being infected with PR8 at MOI of 1. Lane A, a 1-h virus adsorption
step was performed at 37°C followed by an acid wash step following inoculum removal to destroy uninternalized virus. All samples were harvested
at 10 hpi and titrated by plaque assay. Data shown as means  standard errors of the means of data representing fold change with respect to
the virus-only sample for 5 independent recombinant protein preparations. (B) CEF cells infected with PR8 at MOI of 1 were lysed and Western
blotting was performed as indicated. (C) CEF cells were infected as described for panel B and lysed at the indicated time points, and total RNA
was extracted. qRT-PCR was performed for PR8 segment 2 (Seg 2) and Seg 7 RNAs, and values were normalized to chicken actin transcripts. Data
shown are means  standard errors of the means of results from 2 independent protein preparations and primary cell isolations. (D and E) CEF
cells were infected as described for panel B, and cell lysate was used for extraction of RNA and assay of virus titers at the indicated times. Copies
of viral genomic RNA from segments 2 and 7 were quantitated by qRT-PCR (D), and genome copy number-to-PFU ratios were calculated (E). Data
shown are means  standard errors of the means of results from 3 independent protein preparations and primary cell isolations. Single asterisks
(*) and double asterisks (**) indicate P values of 0.05 and 0.01, respectively, as assessed by one-way ANOVA and Dunn’s multiple-comparison
test.
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partially purified virus preparations with either uncleaved or cleaved HA were treated
with either rlipase 1 or trypsin. However, no HA cleavage was detected in the presence
of rlipase 1 (Fig. S5C).
The finding that the proviral effect of lipase 1 depended on its enzymatic activity
suggested the hypothesis that it might affect the process of virus budding through the
plasma membrane. Consistent with this, analysis of the cell surface by scanning
electron microscopy (SEM) showed that, at 8 h after infection with PR8, there were
notably more virus particles budding from cells treated with active rlipase 1 than with
from those treated with the catalytically inert version of the protein (Fig. 5A). The PR8
strain of IAV produces only spherical virus particles, but most human clinical strains of
IAV also produce micrometer-length filamentous particles (25). To examine the cells for
effects on this form of virus budding, we utilized a filamentous derivative of PR8 (PR8
MUd) containing segment 7 from the filamentous virus A/Udorn/307/1972 (26, 27).
Treatment of PR8 MUd-infected CEF cells with active rlipase 1 but not inactive rlipase
1 resulted in a significant increase in the number of infected cells producing viral
filaments, as well as in the length of the filaments (Fig. 5B and C). Thus, overall, the
results showed that rlipase 1 acts late in the viral life cycle to favorably modulate IAV
morphogenesis.
Lipase 1 can enhance IAV vaccine production in ovo. In order to examine the
effect of lipase 1 in vivo, we initially utilized a murine model of IAV-S. aureus coinfection
where bacteria were introduced 1 day after IAV infection, but there were no significant
differences in weight loss or clinical scores and we saw only a moderate increase in viral
FIG 5 Lipase 1 positively modulates virus budding. (A) CEF cells were infected with PR8 at an MOI of 3
and treated with a final concentration of 300 nM active or inactive (S408A) rlipase 1, and at 8 hpi, cells
were fixed and processed for SEM. Representative images are shown at magnification of 10,000. The
scale bar indicates 2 m. (B and C) CEF cells were infected with PR8 MUd at MOI of 3 treated with rlipase
1 or buffer as described above, and cells were fixed at 8 hpi and subjected to surface staining with an
anti-PR8 antibody. Cells were imaged on a Leica confocal microscope. White arrows indicate viral
filaments, and red arrows indicate cellular retraction fibers. Scale bar, 20 m. (C) Images from panel B
were analyzed, and the number of filament-producing cells and the filament length were determined. A
minimum of 60 cells were counted and a minimum of 60 filaments measured from 3 independent
experiments. A single asterisk (*) indicates a P value of 0.05, and triple asterisks (***) indicate a P value
of 0.001, based on a one-way ANOVA.
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titer in the coinfected animals, regardless of the presence or absence of lipase 1
(Fig. S6). In addition, complete bacterial clearance had occurred by day 2 postcoinfec-
tion (data not shown). Animal models of IAV-S. aureus coinfection are limited in their
capacity to recapitulate the conditions of human respiratory infection (8). Furthermore,
a number of studies have indicated that conventional mouse models have major
limitations for the study of S. aureus, due to immune system activation or receptor
incompatibility for S. aureus effector proteins (28, 29). Accordingly, we next employed
another established in vivo system of IAV replication—embryonated hen’s eggs. Im-
portantly, this system is also used for the commercial production of IAV vaccine, so we
used a reassortant virus with glycoprotein genes from the 2009 H1N1 pandemic isolate
A/California/07/2009 and the remaining segments from PR8 to mimic a vaccine strain
of IAV (30). Addition of 100 nM rlipase 1 to 10-day-old embryonated eggs did not
result in toxicity to the embryos (data not shown). Addition of rlipase 1 to eggs infected
with the reassortant virus resulted in increased average HA titers compared to virus-
only samples, although the results did not reach statistical significance (Fig. 6A).
However, an assessment of the amounts of HA1 in partially purified virus preparations
by Western blotting following deglycosylation (30) showed that the addition of rlipase
1 greatly improved the yield of the vaccine antigen (Fig. 6B). Quantification of HA1 from
replicate experiments revealed a 5-fold increase in protein yield following treatment
with rlipase 1 (Fig. 6C). Thus, rlipase 1 enhanced IAV replication in vivo, in a manner
similar to that observed in vitro, regardless of the presence of proteases in ovo that
cleave IAV HA and facilitate multicycle infection. Importantly, these findings suggest a
potential application of rlipase 1 activity for the enhancement of IAV vaccine yield,
which is currently a major limitation of standard methods for the production of
influenza vaccines.
DISCUSSION
Secondary S. aureus infection is a major cause of morbidity and mortality in patients
with influenza. A previous report indicated that an unidentified protease from S. aureus
strain Wood 46 was responsible for enhanced IAV replication in primary avian cells (17).
Here, we demonstrated that S. aureus lipase 1 enhances IAV replication during infection
of primary human and avian cells ex vivo and in ovo and that this activity is independent
of known secreted proteases. Instead, our data indicate that S. aureus lipase 1 is
responsible for this proviral effect and that this applies to a broad array of IAV subtypes
of mammalian and avian origin (Table 1). Lipase 1 is one of the most abundantly
expressed proteins secreted by the USA300 S. aureus strain (18), but an understanding
of its biological role is lacking. In vivo expression has been implied due to detection of
FIG 6 Lipase 1 enhances IAV replication in ovo. (A) Groups of 4 to 6 10-day-old embryonated eggs were infected
with 100 PFU of a Cal07:PR8 6:2 reassortant virus (pH1N1), and a final concentration of 100 nM rlipase 1 or 50 mM
Tris was added to the virus. Eggs were chilled 48 h later, and allantoic fluid was harvested and HA titer determined.
(B) Samples from the experiment described in panel A were pooled, virus was partially purified through a sucrose
cushion, and HA was deglycosylated prior to Western blotting for HA. Representative images are shown. (C) The
signal intensity of Western blot bands was quantified. Data shown are from 3 independent experiments performed
with separate protein preparations, including 4 to 6 eggs per group per experiment. A single asterisk (*) indicates
a P value of 0.05, based on paired Student’s t tests.
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circulating anti-lipase antibodies (31, 32), and lipolytic activity on short-chain triglyc-
erides has been reported, although the kinetics data suggest that it has lower activity
than lipase 2 (18, 22, 33, 34). The specific lipolytic activity of lipase 2 has also been
shown to prevent innate immune cell activation by inactivating bacterial lipoproteins
and thus blocking recognition by macrophages (35). However, to date, no role for lipase
1 in the pathogenesis of S. aureus has been identified. Here, we provide the first report
of a role for lipase 1 activity during coinfection with IAV.
Our data indicate that the effect of lipase 1 on IAV occurs during the late stages of
virus replication. We propose that lipase 1 acts by modifying host cell lipids in the cell
plasma membrane, leading to more efficient budding and to production of an in-
creased number of infectious IAV particles per replication cycle. Although understand-
ing of IAV assembly and particle budding is incomplete (36), membrane modulation is
required for the formation and release of new particles, and specific lipid structures, in
and out of lipid rafts (37–40), have been implicated as preferred budding sites.
Conversely, previous work has indicated that budding of the virus can be altered both
positively and negatively by perturbation of membrane composition (41). The lipase
1-mediated phenotype was observed only in primary fibroblast cells, and it is possible
that the lipids modified by lipase 1 are not present or are differentially regulated in
immortalized cells. Indeed, immortalized cells have been reported to have numerous
attenuations affecting innate intracellular immunity (42) and the lipid composition of
membranes (43). This is consistent with the differences in proviral activity between
lipase 1 and lipase 2, which have been shown to have different substrate preferences
(5, 18). The apparent specificity of lipase 1 for fibroblast cells is noteworthy, as these
cells are present in most lung spaces and account for about 10 to 20% of all lung cells
(44, 45) and have been demonstrated to be recruited during IAV infection (46).
Furthermore, the effect of lipase 1 on fibroblasts could partially reflect the specific
timing of bacterial coinfection. Coinfection by S. aureus normally occurs around day 7
of IAV infection, after the viral peak (47), at a time when the lung environment begins
tissue repair. Lung repair is spearheaded by fibroblasts, and these cells are recruited
heavily to sites of virus-induced damage (48). As such, the increase in levels of available
target cells may exacerbate the effect of lipase 1 during coinfection, resulting in the
resurgence of viral titer observed during coinfection (8, 47).
The proviral activity of rlipase 1 for NHLF cells ex vivo further suggests a potential
role during human clinical infection, and the enhanced virus replication in ovo indicates
the relevance of the lipase 1 activity for IAV in a complex in vivo environment. Animal
models have demonstrated disease exacerbation upon coinfection (47), and expression
of lipase 1, which is widespread in S. aureus (see Fig. S4 in the supplemental material),
has been suggested to occur during human infection, based on the detection of
antibodies (31, 32). Accordingly, we suggest that S. aureus superinfection of humans
with influenza may lead to a lipase 1-mediated enhancement of virus replication,
resulting in a more prolonged and severe infection. Furthermore, the damage caused
by the increased IAV replication in fibroblasts in the lung may lead to increased
occurrence of fibrosis, which has been demonstrated during bacterial coinfection (10).
Additionally, IAV-S. pneumoniae coinfection models have demonstrated the viral neur-
aminidase can cleave sialic acid (49), which bacteria can utilize as an energy source (50),
and IAV infection also results in an increase in levels of host adhesion molecules, such
as fibronectin (51), that both S. pneumoniae and S. aureus can bind. Therefore, en-
hanced virus replication could facilitate the spread and replication of bacteria, suggest-
ing an indirect beneficial role for lipase 1 in the pathogenesis of S. aureus during
coinfection. Although it is well established that secondary bacterial pneumonia is a
major cause of mortality during IAV epidemics, animal models of IAV-S. aureus infection
have offered differing pictures of the outcome of coinfection. While some murine
models have demonstrated increased severity of S. aureus respiratory disease when
preceded by IAV infection (52), in a cynomolgus macaque model, prior infection with
IAV did not predispose the animals to more-severe infection with S. aureus USA300 (53).
The authors concluded that the distinct observations made compared to human clinical
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and rodent model data may have been due to variation in the strain of virus employed
or to a host species-specific effect on susceptibility to IAV or S. aureus infection.
Alternatively, it was suggested that the findings may indicate that unknown comor-
bidities are required to promote the synergistic effect of IAV-S. aureus coinfection (53).
Although we did not see an effect of lipase 1 in the murine coinfection model
employed in the current study, this may have been due to the timing of bacterial
challenge relative to IAV infection, prior to the maximal recruitment of fibroblasts, or to
general limitations of the murine model for replicating human respiratory infection as
previously established (8, 28, 29). Furthermore, the bacteria were rapidly cleared from
the lungs and levels of lipase 1 expression may not have been sufficient to mediate a
proviral effect. However, using an established embryonated egg model, a clear proviral
effect for rlipase 1 was identified in vivo. This observation suggests that a potential
application of the current finding is the utilization of rlipase 1 as a growth enhancer for
IAV vaccine production. Vaccine production can be inefficient, particularly with recent
H1N1 and H3N2 isolates, which grow poorly in eggs due to receptor incompatibilities
(54, 55). The use of rlipase 1 could significantly enhance the yield of poorly growing
viruses, as demonstrated here with the pandemic 2009 H1N1 reassortant virus (Fig. 6).
Of note, in vitro data obtained from studies performed with CEF cells indicated that
rlipase 1 was active on avian strains of IAV (Table 1), which could be a considerable
advantage in the event of an influenza pandemic caused by a strain bearing an avian
strain-derived HA (56).
The threat of another global influenza pandemic is ongoing, and bacterial coinfec-
tion is a frequent and major complication of primary IAV infection. The rise of antibiotic
resistance in bacterial pathogens, such as MRSA, is a further threat with respect to
enhancement of IAV morbidity and mortality. In conclusion, we report the first example
of a secreted staphylococcal factor that enhances IAV replication and that could
represent a target for combination therapy to reduce the severity of IAV-S. aureus
coinfection. In addition, the novel proviral activity could be applied to address global
IAV vaccine shortages which are a major public health concern in the light of the threat
of a global pandemic.
MATERIALS AND METHODS
Tissue culture. Madin-Darby canine kidney (MDCK) cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) (Millipore-Sigma, United Kingdom) with 5% (vol/vol) fetal calf serum (FCS)
(Invitrogen, United Kingdom) and 1% (vol/vol) penicillin/streptomycin/glutamine (PSG) (Invitrogen,
United Kingdom) at 37°C and 5% CO2. A549 and DF1 cells were maintained in DMEM–10% (vol/vol)
FCS–1% (vol/vol) penicillin/streptomycin (PS) (Invitrogen, United Kingdom). Chicken embryo fibroblast
(CEF) cells were isolated as previously described (57) with some modifications. Briefly, macerated
10-day-old embryos were incubated in trypsin/EDTA for 30 min at 37°C and 5% CO2 and passed through
a 100-m-pore-size cell strainer (GE Healthcare, United Kingdom) to yield a single-cell suspension.
Freshly isolated cells were maintained in M199 medium (Millipore-Sigma, United Kingdom)–4% (vol/vol)
FCS–1% PS. CEF cells were used up to passage 6. Primary normal human lung fibroblast (NHLF) cells were
purchased from Lonza, United Kingdom, and maintained in fibroblast growth medium, as recommended
by the manufacturer. HBTECs were purchased from ATCC and cultured in airway epithelial cell basal
medium supplemented with a bronchial epithelial cell growth kit (ATCC, USA). Cells were used at 80%
confluence for infections.
Influenza A virus. PR8, A/Udorn/307/72, A/Mallard/Netherlands/10/99, the PR8 MUd 7:1 reassortant
between PR8 and A/Udorn/307/72, and a 6:2 reassortant between PR8 and A/California/07/2009 strain
IAVs were generated from plasmid clones by reverse genetics (30, 58–60). Other strains of IAV were
available in the laboratory collection (61) or generously supplied by Wendy Barclay (62). For generation
of infectious IAV stocks, a multiplicity of infection (MOI) of 0.01 was used to infect MDCK cells for 1 h at
37°C and 5% CO2. Cells were washed, serum-free medium–2.5 g/ml N-acetyl trypsin (NAT) (Millipore-
Sigma, United Kingdom) was added, and infections were allowed to proceed for 48 h. Supernatant was
harvested, centrifuged at 4,000 g for 10 min, and stored at 80°C until further use. Egg-grown stocks
were generated by infection of 11-day-old embryonated hen’s eggs (Henry Stewart, United Kingdom)
with 100 PFU of virus. At 2 days postinfection, eggs were chilled and allantoic fluid was harvested,
centrifuged twice at 4,000 g for 10 min, and stored at 80°C until further use. Infectious viral titers
were determined by plaque assay on MDCK cells, under an agarose overlay (63). To obtain a PR8 stock
with uncleaved HA, infection was performed at an MOI of 3. After the inoculum was removed, cells were
washed twice with phosphate-buffered saline (PBS), subjected to a 1-min wash using acid (10 mM HCl,
150 mM NaCl [pH 3]), and washed 3 times with PBS, after which serum-free medium without trypsin was
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added. Supernatant was harvested at 24 hpi and virus partially purified by ultracentrifugation as
described below.
Bacterial growth. The bacterial strains used in this study are listed in Table S2 in the supplemental
material. S. aureus isolates were grown overnight (O/N) on tryptic soya agar (TSA) or in tryptic soya broth
(TSB) at 37°C with shaking at 200 rpm unless otherwise stated. E. coli isolates were grown on Luria-Bertani
(LB) agar or in LB broth as described above. Where appropriate, medium was supplemented with
antibiotics—ampicillin at 100 g/ml, erythromycin at 10 g/ml, or chloramphenicol at 12 g/ml.
Strain construction. For complementation of Tn insertion mutants, full-length genes were amplified
with primer pair Lip1 F and Lip 1 R and primer pair Lip 2 F and Lip 2 R (Table S3) and ligated into the
pALC2073 vector (64). Plasmids were isolated with a Qiagen Spin Miniprep kit (Qiagen, United Kingdom)
and transformed into S. aureus strain RN4220, from which they were transferred to appropriate S. aureus
recipient strains by generalized transduction performed with phage 80 (65).
For the generation of recombinant proteins, the lipase 1 and lipase 2 genes, without their signal
peptide sequences, were amplified as described above, using primer pair rLip1 F and rLip1 R and primer
pair rLip2F and rLip2R (Table S3), respectively, and inserted into pET15b vector, prior to transformation
into E. coli DH5. Plasmid was isolated and freshly transformed into E. coli BL21(DE3) cells prior to each
induction. For site-directed mutagenesis, plasmid pET15b::lipase 1 was used with a QuikChange Light-
ning kit (Agilent Technologies, United Kingdom) per the manufacturer’s instructions.
Protein isolation and expression. For SEC, overnight (O/N) cultures in TSB were centrifuged at
4,000 g for 15 min and filtered through a 0.45-m-pore-size filter (Millipore, United Kingdom) and the
supernatant was concentrated (5-to-7-fold) by the use of Amicon Ultra centrifugal units (10-kDa cutoff)
to reach a total volume of 10 ml. Volumes (10 ml) of the concentrated supernatant were then loaded on
a Superdex 75-pg size exclusion column (GE Healthcare, United Kingdom) equilibrated with 50 mM Tris
(pH 7.5). Fractions (10 ml) were collected at a flow rate of 2.5 ml/min. Following chromatography,
protein-containing fractions were subjected to ethanol precipitation. Briefly, 4 volumes of 100% ethanol
were added to each fraction, and the fraction was frozen at 20°C for 4 h, centrifuged at 4,000 g for
45 min, and resuspended in 1/10 the original volume in 50 mM Tris (pH 7.5). For SEC of complemented
strains, cultures were grown in TSB to an optical density at 600 nm (OD600) of 0.6 to 0.8, induced with
125 ng/ml of tetracycline O/N, and processed as described above.
IEC was performed on S. aureus USA300 WT SEC fractions 2 to 4, which were combined and separated
on a SP Sepharose column (GE Healthcare, United Kingdom) equilibrated with 50 mM Tris (pH 8.0). An
elution gradient of 0% to 50% buffer (20 mM Tris [pH 8.0]–1 M NaCl) was used at a flow rate of 2.5 ml/min,
and 5-ml fractions were collected. Fractions were subjected to ethanol precipitation as described above
prior to use.
Recombinant protein was purified from cultures of E. coli BL21. Briefly, 1-liter cultures were grown in
LB with 100 g/ml ampicillin until an OD600 of 0.6 to 0.8 was reached. Cultures were then induced with
1 mM IPTG (isopropyl--D-thiogalactopyranoside) for 4 h, pelleted, and frozen at 20°C. When required,
pellets were defrosted, resuspended in 50 ml lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM
imidazole) with complete protease inhibitor (Roche, United Kingdom), passed through a One-Shot cell
disruptor (Constant Systems, Northants, United Kingdom) at 30,000 lb/in2, centrifuged at 4,000 g for
30 min, and passed through a 0.45-m-pore-size filter. Proteins were purified by immobilized metal
affinity chromatography (IMAC) performed with a FF Crude nickel-nitrilotriacetic acid (Ni-NTA) column
(GE Healthcare, United Kingdom). The flow rate was 2.5 ml/min, with an elution gradient of 0% to 100%
buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole) over 30 min. Protein was dialyzed in 50 mM
Tris (pH 7.5) using Spectra/Por Float-a-Lyzer tubing with an 8,000-to-10,000-molecular-weight cutoff
(Spectrum Laboratories, CA, USA). Relative protein concentrations were estimated by the use of a
bicinchoninic acid (BCA) protein assay kit (Novagen, United Kingdom) following the manufacturer’s
instructions.
For studies performed with IEC or SEC fractions, CEF cells were infected at MOI 0.01 and 50-l
volumes of ethanol-concentrated fractions were added to 1 ml of serum-free media. For studies per-
formed with recombinant protein, 50-l volumes of concentrated stock were added to 1 ml of serum-free
medium to reach the final indicated concentration. Infections performed at MOI 0.01 were harvested at
48 h and those at MOI 3 at 24 h.
Egg infections. Embryonated hen’s eggs (Henry-Stewart, United Kingdom) (10 days old) were used
for all infections performed with rlipase 1. The eggs were infected with 100 PFU and 100 nM rlipase 1
(assuming an allantoic fluid volume of 10 ml) or with buffer to reach a total volume of 100 l. The eggs
were incubated for a further 48 h at 35°C and chilled O/N at 4°C, and allantoic fluid ws harvested. HA
assays were performed as previously described (30). For partial purification of virus, the allantoic fluid
from 4 or 5 eggs was pooled, clarified twice by centrifugation at 2,000 g for 5 min, and loaded onto
a 30% sucrose cushion. Centrifugation was carried out at 4°C and 28,000 rpm for 3 h on a Beckman XL-71
machine (Beckman, United Kingdom) (SW28 rotor). Supernatant and sucrose were aspirated, and the
tube was filled with PBS, followed by centrifugation at 28,000 rpm at 4°C for 1 h. PBS was removed, 300 l
of PBS ws added, and the pellet was allowed to lift at 4°C overnight. All samples were then equalized to
the same volume before treatment was performed with N-glycosidase F (PNGase F; New England
Biolabs), according to the manufacturer’s protocol.
RNA isolation and quantitative real-time PCR (qRT-PCR). CEF cells were infected with PR8 at an
MOI of 3 or were subjected to mock infection. Addition of rlipase 1 or rlipase 1 S408A was performed to
reach a final concentration of 300 nM after inoculum removal, per the standard protocol. At 6 h and 8
h postinfection, the supernatant was harvested and the cells were washed twice with PBS and lysed in
RLT buffer with 143 M -mercaptoethanol (Qiagen, United Kingdom) (500 l/well for a 6-well plate).
Goncheva et al. ®
July/August 2020 Volume 11 Issue 4 e00975-20 mbio.asm.org 12
 o
n
 July 14, 2020 by guest
http://m
bio.asm
.org/
D
ow
nloaded from
 
Samples were processed with a QIAshredder (Qiagen, United Kingdom), and RNA was extracted with an
RNeasy kit (Qiagen, United Kingdom), according to the manufacturer’s instructions, with a DNase step
included on the column. cDNA was generated with a SuperScript VILO cDNA synthesis kit (Thermo Fisher,
United Kingdom) in a 100-l volume, per the manufacturer’s instructions, using 500 ng RNA per cDNA
reaction. A 5-l volume of a 1-in-4 dilution of the cDNA was used for quantitative PCRs (qPCRs) with
FastStart universal SYBR green master mix (Roche, United Kingdom). qPCRs were performed in 20-l
reaction volumes with 400 nM forward primer and 500 nM reverse primer for the M1 and chicken actin
genes (Table S2) and 300 nM forward primer and 300 nM reverse primer for the PB1 gene (Table S3).
qPCR conditions consisted of 1 cycle at 95°C for 10 min and 40 cycles of 95°C for 10 s followed by 50 s
at annealing temperature (Table S4), with fluorescence acquisition performed at the annealing step, on
a Rotor-Gene Q PCR machine (Qiagen, United Kingdom). Analysis was performed in triplicate, with the
average value taken and normalized to chicken actin gene levels to give threshold cycle (ΔCT) values.
Western blotting analyses. CEF cells in 6-well plates were infected with PR8 at MOI of 1 and treated
with 300 nM rlipase 1 as the standard. At 6, 8, and 10 h postinfection (hpi), cells were washed with PBS
and lysed in 200 l 2 Laemmli buffer (Sigma-Aldrich, United Kingdom). Protein was separated on a 12%
SDS-PAGE gel and transferred to a nitrocellulose membrane (GE Healthcare, United Kingdom) by the use
of a Trans-Blot Turbo blotting system (Bio-Rad, United Kingdom), according to the manufacturer’s
instructions. Membranes were incubated for 60 min in PBS–0.1% Tween 20 (Sigma-Aldrich, United
Kingdom) (PBST)–5% (wt/vol) dried milk (Sigma-Aldrich, United Kingdom) and washed 3 times with PBST.
Primary antibody mixed in PBST was added, followed by incubation for 2 h at room temperature or O/N
at 4°C. For detection of viral proteins, in-house rabbit sera (PB1, PB2, M1, and whole anti-PR8 virus sera
for HA0), 1:500 anti-NP, 1:250 mouse monoclonal antibody 14C2 (M2), and 1:1,000 goat polyclonal
anti-IAV H1N1 virus antibody (AbD Serotec 5315-0064) were used as primary antibodies. Tubulin was
detected with a rat anti-tubulin antibody (Bio-Rad, United Kingdom) (1:1,000). HA from the H1N1 2009
pandemic virus (pH1N1) was detected with a rabbit polyclonal anti-swine H1 HA antibody (Ab91641;
Abcam) (1:500). Rlipase 1 was used for the generation of a rabbit polyclonal antibody (Eurogentec,
Belgium), using a proprietary 28-day program. The antibody was used at a 1:3,300 dilution to detect
lipase 1 expression. Membranes were then washed 3 times for 5 min each time in PBST followed by
incubation for 45 to 60 min with secondary antibody (donkey anti-rabbit antibody [IRDye 800RD] or goat
anti-rat antibody [IRDye 680RD]; Li-Cor, United Kingdom) diluted in PBST before a further 5 or 6 washes
with PBST and imaging on an infrared scanner (Li-Cor, United Kingdom) were performed.
Confocal and scanning electron microscopy. CEF cells were seeded at a density of 1 105
cells/well on glass coverslips the day prior to infection. Cells were infected at an MOI of 3, and rlipase 1
was added to reach a concentration of 300 nM immediately after inoculum removal. For confocal
microscopy, cells were fixed with 4% paraformaldehyde for 20 min at 8 hpi. Cells were washed 3 times
with PBS–1% FBS and incubated with rabbit anti-PR8 antibody at 1:500 for 1 h at room temperature.
Following 3 washes with PBS–1% FBS, cells were incubated with Alexa Fluor 488-conjugated anti-rabbit
secondary antibody (Thermo Fisher [A-21206]) (1:1,000) and DAPI (4=,6-diamidino-2-phenylindole) (In-
vitrogen) (1:10.000) for 45 min at room temperature. Cells were washed as described above, and the glass
coverslips were mounted on microscope slides using approximately 5 l of ProLong antifade reagent
(Invitrogen). The cells were imaged in a Leica LSM710 confocal microscope using a 63 lens objective.
Images were collected as z-stacks across the depth of the cell membrane, generally in 0.45-m
increments, and are presented as maximum intensity projections. For counting the number of infected
cells, a minimum of 60 cells were scored for the presence or absence of viral filaments. For measurement
of filament length, a minimum of 60 filaments were measured using Image J (66). For scanning electron
microscopy, cells were fixed with 3% glutaraldehyde–0.1 M sodium cacodylate buffer (pH 7.3) O/N and
then washed 3 times for 10 min each time with 0.1 M sodium cacodylate buffer. Samples were then
postfixed in 1% osmium tetroxide–0.1 M sodium cacodylate buffer for 45 min. A further 3 washes (10 min
each) were performed in 0.1 M sodium cacodylate buffer. Cells were dehydrated in graded concentra-
tions of acetone (once each at 50%, 70%, and 90% and 3 times at 100%) for 10 min each time followed
by critical point drying using liquid carbon dioxide. After mounting of the specimens on aluminum stubs
with carbon tabs attached, they were sputter coated with 20-nm-diameter gold palladium particles and
viewed using a Hitachi S-4700 scanning electron microscope.
Lipase assays. Lipase assays were performed using purified recombinant protein as previously
described (67). Individual reaction mixtures contained 36 l of Tween 20 as the substrate (diluted 1 in 10
in 20 mM Tris-HCl), 30 l of 100 mM CaCl2, 84 l of 20 mM Tris (pH 8), and 50 l recombinant protein at
the indicated concentrations. The reaction mixtures were incubated at 37°C in an Optima plate reader
(Fluostar, United Kingdom), with shaking performed every 3 min. Optical density measurements at OD495
were obtained every 5 min for a period of 24 h.
Mouse infections. All work involving animals was carried out under a United Kingdom Home Office
license according to the Animals (Scientific Procedures) Act of 1986. Female BALB/c mice (10 to 12 weeks
of age) were anaesthetized with isoflurane (Merial Animal Health Ltd.) and intranasally infected with virus
(10 PFU) or bacteria (1 107 CFU) in a mixture with 40 l PBS (Gibco, United Kingdom). Mice were
weighed daily and scored for visual signs of clinical disease, including inactivity, ruffled fur, and labored
breathing. Clinical scores were quantitated on a scale of 0 to 3, and daily scores were added together.
Animals that had exhibited severe clinical signs or had lost 25% to 30% of their original body weight
were euthanized by CO2 asphyxiation. Lungs were removed and homogenized in PBS in a Qiagen Tissue
Lyser II instrument run at 28 shakes/s for 4 min (2 runs of 2 min). The resulting lysate was centrifuged at
3,000 g for 5 min and supernatant collected. Viral titers were determined by a standard plaque assay
performed on MDCK cells.
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Statistical methods. Statistical analysis was performed with GraphPad Prism 7 or GraphPad Prism 8
software (GraphPad, USA).
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